Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
February 02, 2021 08:00 ET | Source: Protara Therapeutics Protara Therapeutics New York, New York, UNITED STATES
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare industry, most recently serving as Chief Commercial Officer at ZS Pharma.
“It is with great excitement that we welcome Cynthia to our Board of Directors,” said Jesse Shefferman
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MakeMyTrip Limited Announces Pricing of Upsized $200 Million 0.00% Convertible Senior Notes due 2028
MakeMyTrip.com, Inc.February 5, 2021 GMT
New York, Feb. 05, 2021 (GLOBE NEWSWIRE) Gurugram, India, February 5, 2021 / New York, February 5, 2021 MakeMyTrip Limited (Nasdaq: MMYT) (“MMYT” or the “Company”) today announced the pricing of $200 million in aggregate principal amount of 0.00% convertible senior notes due 2028 (the “Notes” and the “Notes Offering”, respectively). The Notes Offering was upsized from the previously announced offering of $175 million in aggregate principal amount of the Notes. In connection with the Notes Offering, the Company has granted to the initial purchasers of the Notes a 30-day option to purchase up to an additional $30 million in aggregate principal amount of the Notes. The sale of the Notes to the initial purchasers is expected to settle
Appointment of Executive Vice President: SA gold operations so-co-it.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from so-co-it.com Daily Mail and Mail on Sunday newspapers.
23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics
February 4, 2021
23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development
Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe’s consumer health and therapeutics businesses
The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion